Monday, 20 January 2020

The first full day of the Congress, open to Industry and Standard ticket holders, focuses on the latest in EB research – including current challenges, therapeutics, and a clinical trial update.

For any queries related to the programme, please email programme@ebworldcongress.org.

Please note: The Congress programme is subject to change.

Programme overview

08:30 | WELCOME
Chair: Jouni Uitto
Challenges and unmet needs – the breadth of preclinical work ongoing
Jouni Uitto
08:40 | CLASSIFICATION
Chair: Jo-David Fine
EB classification and updates from the 2019 classification meeting
Cristina Has
09:00 | CURRENT DILEMMAS – THE COMPLEXITY OF EB (panel debate)
Chair: Jo-David Fine
EB as a systemic disease – implications for research
Johann Bauer

Modelling EB in the research environment
Leena Bruckner-Tuderman

Curative vs disease modifying strategies
Jakub Tolar

Panel debate
How to focus; avoid being spread too thinly because of complexity; where and how to direct the research
09:30 | COFFEE BREAK
10:00 | THE CHALLENGES OF EB SKIN
Chair: Peter Marinkovich
Wound healing mechanisms – macrophages
Sabine Eming

Immune function and bacterial challenge
Josefine Hirschfeld

Models of EB skin for pre-clinical studies
Marcela del Rio

Learnings from other diseases (cell inflammation)
David Abraham

Panel discussion
11:05 | INFLAMMATION, FIBROSIS & THERAPEUTICS
Chair: Leena Bruckner-Tuderman
Fibrosis in EB – mechanisms and anti-fibrotic strategies
Alexander Nyström

Losartan for RDEB trial – results and international perspectives
Dimitra Kiritsi

miRNA in EB
Giovanna Zambruno

Oral presentations

Discussion
12:15 | LUNCH
13:15 | CANCER & CANCER THERAPEUTICS
Chair: Johann Bauer
KEYNOTE: Precision medicine for SCC
Kevin Harrington

Genetic overview/current RDEB knowledge
Andy South

Interdisciplinary management and therapies for EB associated cancers (skin, mucosal, internal)
Leena Bruckner-Tuderman

RDEB-SCC protocols (rigosertib, pembrolizumab, cetuximab, & nivolumab – SCC cream)
Jemima Mellerio

Oral presentations

Panel discussion
15:00 | TEA BREAK
15:30 | THERAPEUTICS
Chair: Jouni Uitto
EBS target and treatment options/targeting EB as an inflammatory disease
Thomas Magin

Read-through therapeutics – Amlexanox and Gentamicin – considerations for drug repurposing
David Woodley

Topical treatments – an update
Dedee Murrell
16:10 | NATURAL HISTORY – IMPLICATIONS FOR CLINICAL TRIAL DESIGN
PEBLES
Jemima Mellerio

EB Clinical Research Consortium and the North American EB database
Anna Bruckner

Discussion
16:45 | CLOSE
X
//]]>